Quantcast

Fontus Acquires Thyroid Drug From Roche

June 17, 2008

Fontus Pharmaceuticals, a specialty pharmaceutical company focused on nephrology and endocrinology, has acquired Rocaltrol from Roche Laboratories.

Rocaltrol is a vitamin D analog prescribed by nephrologists for the management of hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure and by endocrinologists for the management of hypocalcemia in patients with post-surgical hypoparathyroidism, idiopathic hypoparathyroidism and pseudohypoparathyroidism.




comments powered by Disqus